CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program

Secondary acute myeloid leukemia (sAML) poorly responds to conventional treatments and allogeneic stem cell transplantation (HSCT). We evaluated toxicity and efficacy of CPX-351 in 71 elderly patients (median age 66 years) with sAML enrolled in the Italian Named (Compassionate) Use Program. Sixty da...

Descripción completa

Detalles Bibliográficos
Autores principales: Guolo, Fabio, Fianchi, Luana, Minetto, Paola, Clavio, Marino, Gottardi, Michele, Galimberti, Sara, Rizzuto, Giuliana, Rondoni, Michela, Bertani, Giambattista, Dargenio, Michela, Bilio, Atto, Scappini, Barbara, Zappasodi, Patrizia, Scattolin, Anna Maria, Grimaldi, Francesco, Pietrantuono, Giuseppe, Musto, Pellegrino, Cerrano, Marco, D’Ardia, Stefano, Audisio, Ernesta, Cignetti, Alessandro, Pasciolla, Crescenza, Pavesi, Francesca, Candoni, Anna, Gurreri, Carmela, Morselli, Monica, Alati, Caterina, Fracchiolla, Nicola, Rossi, Giovanni, Caizzi, Manuela, Carnevale-Schianca, Fabrizio, Tafuri, Agostino, Rossi, Giuseppe, Ferrara, Felicetto, Pagano, Livio, Lemoli, Roberto Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538937/
https://www.ncbi.nlm.nih.gov/pubmed/33024084
http://dx.doi.org/10.1038/s41408-020-00361-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538937/
https://www.ncbi.nlm.nih.gov/pubmed/33024084
http://dx.doi.org/10.1038/s41408-020-00361-8

Ejemplares similares